How to Buy Puma Biotechnology Stock
Puma Biotechnology Inc
Puma Biotechnology, Inc. , a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Puma Biotechnology stock last closed at $3.01, up 5.24% from the previous day, and has decreased 41.78% in one year. It has overperformed other stocks in the Biotechnology industry by 0.35 percentage points. Puma Biotechnology stock is currently +35.28% from its 52-week low of $2.23, and -42.78% from its 52-week high of $5.26.
As of Apr 22, 2025, there are 49.61M shares of PBYI outstanding. The market capitalization of PBYI is $149.33M. In the past 24 hours, 201,123 PBYI shares were traded.
How to Buy Puma Biotechnology Stock
Not sure how to invest in Puma Biotechnology stock? Here's how.
- Decide where to buy Puma Biotechnology stock: You need to pick an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you figure out where to buy Puma Biotechnology stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your brokerage account: Select your payment method and add your info.
- Analyze Puma Biotechnology stock: The Puma Biotechnology ticker symbol is PBYI. Is Puma Biotechnology stock a good investment? Should you buy shares of PBYI? How do PBYI's underlying business fundamentals look? Do top analysts think Puma Biotechnology is a good buy? Why has PBYI's stock price moved recently? (Hint: Our stock research tools can help you evaluate if PBYI is a good stock to buy).
- Execute your PBYI purchase: Decide if you will purchase PBYI shares at the current market price or use a limit order to purchase PBYI shares at a specific price.
- Monitor your PBYI investment: Create a watchlist to important updates regarding your new investment in Puma Biotechnology shares.
Step 1: Decide where to buy Puma Biotechnology stock
You need a brokerage account in order to access the NASDAQ market and buy PBYI stock.
Our recommended brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world markets: From Technology to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've picked the right brokerage, the next step is to fill out some personal info so you are able to buy PBYI today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to start a new trading account.
- Submit your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've finished signing up on the best stock broker app, you can securely and quickly fund your account:
Watch the video below if you need help depositing funds into your investment account.
Step 4: Analyze Puma Biotechnology stock
After you have chosen the best place to buy Puma Biotechnology stock, it's important to research their stock prior to investing, so you can understand the risk as well as the upside.
Puma Biotechnology stock at a glance
PBYI Overview
WallStreetZen was designed to help everyday investors do more in-depth fundamental analysis quickly.
You can see all of the due diligence checks on PBYI's stock page.
Is PBYI stock properly valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge PBYI's fair value.
Using relative valuations ratios:
- PBYI may be undervalued based on its P/E ratio of 4.85x, relative to Biotechnology industry P/E ratio of -208.37x
- PBYI may be undervalued based on its P/B ratio of 1.62x, relative to Biotechnology industry P/B ratio of 4.16x
You can do additional valuation analysis on PBYI's stock here.
PBYI Financial Health Summary
Passed Financial Due Diligence Checks:
- There are more short-term assets than short-term liabilities on the PBYI balance sheet.
- PBYI profit margin has gone up from 9.2% to 13.1% in the past year.
- Total PBYI debt is lower than 5 years ago, relative to shareholder equity.
- PBYI's operating cash flow of $38.92M allows it to safely service it's debt of $74.08M.
- There are more short-term assets than long-term liabilities on the PBYI balance sheet.
Failed Financial Due Diligence Checks:
- PBYI earnings of $36.55M is not sufficient to cover its interest payments.
- PBYI has a relatively high debt to equity ratio of 1.32.
Do analysts think it's a good time to buy PBYI stock
Out of 1 Wall Street analysts who track PBYI, the consensus analyst rating on Puma Biotechnology is a Buy
Please note that analyst forecasts are not recommendations, nor are they financial advice.
You can dive deeper into what analysts are projecting on the Puma Biotechnology stock forecast page.
PBYI Trading Indicators
Is PBYI Making Money?
Last year, PBYI earnings were $30.28M. Over the last one years, PBYI's earnings have increased by 34.78% per year. This was faster than the Biotechnology industry average of 10.63%.
Last year, PBYI revenue was $230.47M. Over the past five year, PBYI's revenue has grown by -3.28% per year. This was slower than the Biotechnology industry average of 44.4%.
Dig into PBYI's earnings and revenue performance here.
Latest Insiders Trades at PBYI
In the last year, executives and large shareholders at PBYI have sold more shares than they have bought.
Alan H. Auerbach, President and CEO of PBYI, was the latest PBYI insider to sell. They sold $106,666.83 worth of PBYI stock on Jan 2, 2025.
Learn more about who owns PBYI stock here.
Does PBYI stock generate passive income?
No, Puma Biotechnology doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Execute your PBYI purchase
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are generally fine for most investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a particular price, place a limit order.
Hit the Open button and eToro will place the order.
If you require additional help investing in stocks on eToro, click the how to video below:
Step 6: Monitor your PBYI investment
Now that you own some shares in PBYI, you'll want to stay up-to-date on your new investment.
Create a watchlist to get notified of important updates regarding your PBYI stock.
PBYI Feed
How to Buy Stock in Puma Biotechnology
To summarize, here are the 6 steps for buying Puma Biotechnology stock:
- Decide where to buy Puma Biotechnology stock
- Create your brokerage account
- Fund your brokerage account
- Analyze Puma Biotechnology stock
- Execute your PBYI purchase
- Monitor your PBYI investment
If you are looking for a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get notifications regarding your investment in Puma Biotechnology, create your watchlist below.
Trending Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.